AbbVie vs Bristol-Myers Squibb Showdown | Business and Finance News

AbbVie and Bristol-Myers Squibb are both powerhouse pharma stocks with different strategies—AbbVie’s betting on immunology and aesthetics to move beyond Humira, while BMS focuses on cancer and heart disease. In 2025, AbbVie soared with $61.2B in revenue (up 8.6%) and $4.2B net income, while BMS saw a slight revenue dip but rebounded to $7.1B net income after last year’s loss. Both face patent cliffs and pricing pressure, but AbbVie’s newer drugs are gaining traction, and its neuroscience division is growing. Valuation-wise, BMS looks cheaper (P/E 9.5, P/S 2.7) vs. AbbVie’s more expensive multiples (P/E 17.4, P/S 7.1). For long-term growth and dividend stability, AbbVie edges out as the stronger play right now. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/a940a15c530730aa